Sanofi-Aventis Korea, the local offshoot of the global healthcare company Sanofi, and two of its sister companies held a media event in southern Seoul Wednesday to discuss its progress in developing new drugs.
|Bae Kyung-eun, the general manager of Sanofi-Aventis Korea, introduces her company’s new vision during a media event in southern Seoul Tuesday.|
The company discussed its pipeline while rolling out the company’s new vision as an effort to unify its employees under a single goal of supporting and protecting patients. Sanofi is ranked sixth in the world and fifth in Korea regarding revenue, having raked in around $38.5 billion globally and $404 million domestically, last year.
Sanofi-Aventis Korea is operating five main business divisions – diabetes and cardiovascular, general medicines, consumer healthcare, vaccines (Sanofi Pasteur), and specialty care (Sanofi Genzyme).
The Korean branch of the French pharmaceutical giant said it is developing a pipeline focused mainly on biological products and a variety of treatments effective against multiple diseases, having launched six major products across seven major disease areas between 2015 and 2017.
The company also noted it has 47 drugs in development and is pursuing an “open innovation” strategy. Company officials said they had struck around 40 strategic alliances in nine disease areas with four phase 3 clinical trials underway. One phase 3 trial, for a diabetes drug, is being conducted in partnership with Hanmi Pharmaceuticals, they said.
Sanofi also got U.S. FDA’s approvals for two new drugs – Dupixent for atopic dermatitis, and Kevzara for rheumatoid arthritis – this year. The Korean health authorities also approved Soliqua for diabetes last week, the officials said.
The company entered Korea in 1957 and established a research facility in Daejeon in 2010. It was designated as an innovative pharmaceutical company by the Ministry of Health and Welfare in 2014 based on its performance in developing new and useful drugs, the company said.
<© Korea Biomedical Review, All rights reserved.>